Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia
NCT07536269Phase 2Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crinecerfont in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started Jul 2026; status: recruiting.
02
Drugs
crinecerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07536269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07536269.